Trading Report: Today, Delta Lloyd NV Holds Stake in Teva Pharmaceutical Industries Ltd. (TEVA)

Today, Delta Lloyd NV Holds Stake in Teva Pharmaceutical Industries Ltd. (TEVA)

Delta Lloyd NV maintained its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, according to its most recent filing with the SEC. The firm owned 66,000 shares of the company’s stock at the end of the third quarter. Delta Lloyd NV’s holdings in Teva Pharmaceutical Industries were worth $3,037,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sharkey Howes & Javer boosted its position in shares of Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock valued at $101,000 after buying an additional 358 shares in the last quarter. Hudock Capital Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock valued at $103,000 after buying an additional 564 shares in the last quarter. Washington Trust Bank boosted its position in shares of Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock valued at $103,000 after buying an additional 58 shares in the last quarter. WFG Advisors LP boosted its position in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock valued at $104,000 after buying an additional 256 shares in the last quarter. Finally, Kistler Tiffany Companies LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock valued at $107,000 after buying an additional 64 shares in the last quarter. 63.16% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded up 0.26% on Friday, reaching $38.21. 2,320,750 shares of the company traded hands. Teva Pharmaceutical Industries Ltd. has a one year low of $37.12 and a one year high of $66.55. The company has a market capitalization of $38.78 billion, a PE ratio of 22.23 and a beta of 0.73. The stock’s 50 day moving average price is $41.87 and its 200 day moving average price is $49.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.29 by $0.02. The business earned $5.56 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Teva Pharmaceutical Industries had a net margin of 8.81% and a return on equity of 16.75%. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.35 EPS. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post $5.14 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Shareholders of record on Monday, December 5th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, December 1st. This represents a $1.36 annualized dividend and a yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 50.58%.

Several analysts recently issued reports on the stock. RBC Capital Markets set a $71.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Sunday, September 11th. Bank of America Corp. set a $72.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Saturday, October 1st. Deutsche Bank AG reduced their price target on shares of Teva Pharmaceutical Industries from $68.00 to $54.00 and set a “buy” rating on the stock in a research report on Wednesday, November 16th. Leerink Swann reiterated an “outperform” rating and set a $66.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday, August 16th. Finally, Piper Jaffray Cos. reiterated a “neutral” rating and set a $57.00 price target (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, August 8th. Thirteen research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has an average rating of “Buy” and a consensus target price of $60.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Related posts

Leave a Comment